Drug intelligence / Profile preview

NFS-04

Development stage: Preclinical
Lead developer: Neurophth
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Ophthalmic

Overview

NFS-04 is an investigational adeno-associated virus (AAV) mediated gene therapy being developed by Neurophth Therapeutics (Wuhan Kaidejinuo Biotechnology) for the treatment of glaucoma and optic nerve injury. The therapy is designed to deliver therapeutic genetic material to the retina to promote the survival and regeneration of retinal ganglion cells (RGCs), which are typically damaged or lost in these conditions. By targeting the underlying neurodegeneration, NFS-04 aims to prevent further vision loss and potentially restore visual function. The program is currently in the IND-enabling stage of development.

Beyond the preview

Go deeper on NFS-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NFS-04.

Explore the full profile